Staff
Maricann Group Inc. (MRRCF) announced that Health Canada has granted it a new license that will allow the company to increase capacity to 6,250,000 grams on site at any one time. The annual production limits were approved for medical cannabis products in Maricann’s current Langton, Ontario facility. This new license represents an increase of over 480% of production capacity and is valid until October 9, 2020.
In addition to that, Maricann’s new facility will house an additional two vaults with 30,000,000 grams of potential storage capacity. The new license is a huge jump from the previous limitations that were for a total of 1,282,000 grams (930kg of dried marihuana and 352 kg of cannabis oil) per year.
“This new license gives us more flexibility as we are able to increase production volume and provide more bulk storage for cannabis products, including processed resin to meet future demand,” said Ben Ward, CEO of Maricann. “With the Phase 1 expansion of our state of the art Langton cultivation and production facility nearing completion and with both new vaults now poured and in place, we expect to be able to take full advantage of the scale we are creating. We maintain a highly secure growing environment that meets or exceeds requirements of the Access to Cannabis for Medical Purposes Regulations (ACMPR).”
This re-issued license is one of two that Health Canada has issued to Maricann. On September 5, 2017, Maricann announced that it had secured a second-site sales license for its location in Burlington, Ontario through its wholly-owned subsidiary, Maricann Inc. According to the company statement, the Burlington, Ontario sales license is the second granted to Maricann Inc. by Health Canada, with the first applying to the Company’s cultivation and production facility in Langton, Ontario.
Earlier this week, Maricann announced that it had entered into a collaborative agreement with a national provider that the company didn’t name to create a pharmacy services program that will help pharmacists to counsel and educate patients with regards to medical marijuana.
According to the company statement, “The initiative will aim to position pharmacies to be a preferred access point for medicinal cannabis based on pharmacists’ critical role in working with physicians and patients in understanding the multi-synchronistic opportunities in multi-medication patients. Maricann will develop additional medical cannabis product accessibility initiatives with the objective of establishing procedures and protocols for medicinal cannabis medical documents, and facilitating the submission of patient prescriptions to Maricann for direct to patient fulfillment.”
